Figure 3 | Leukemia

Figure 3

From: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Figure 3

Overall survival in patients with newly diagnosed symptomatic myeloma based on baseline FLC measurement. (a) Overall survival based on rFLC thresholds in 94 patients. ‘High rFLC’ for patients with clonal kappa or lambda disease was 3.6 and 0.02, respectively. (Kyrtsonis MC et al.32 Prognostic value of serum-free light chain ratio at diagnosis in multiple myeloma. Br J Haematol. 2007;137:240–243.) (b) Overall survival based on baseline iFLC terciles in 301 patients undergoing Total Therapy 3. Highest tercile (greater than 750 mg/l) was associated with worse overall survival (van Rhee F et al.29 High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110:827–832.) (c) Event-free survival based on baseline iFLC terciles in 301 patients undergoing Total Therapy 3. Highest tercile (greater than 750 mg/l) was associated with worse overall survival (van Rhee F et al.29 High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110:827–832.) (d) Risk stratification model using elements of the international staging system (ISS) and extreme values of rFLC adds in 790 patients diagnosed with active MM between 1995 and 1998. Patients were assigned 1 point for each of the following: abnormal rFLC (<0.03 or >32); high Sb2 M (3.5 g/l); or low serum albumin (<3.5 g per 100 ml). (Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum-free light chain ratio in patients with newly diagnosed myeloma and proposed incorporation into the International Staging System Submitted).

Back to article page